Terms: = Breast cancer AND EIF3E, eIF3-p46, 3646, ENSG00000104408, EIF3S6, eIF3e, EIF3-P48, INT6 AND Treatment
7 results:
1. Theranostic role of
Yang Q; Chen Z; Qiu Y; Huang W; Wang T; Song L; Sun X; Li C; Xu X; Kang L
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1246-1260. PubMed ID: 38135849
[TBL] [Abstract] [Full Text] [Related]
2. Haploinsufficient tumor suppressor PRP4K is negatively regulated during epithelial-to-mesenchymal transition.
Clarke LE; Cook A; Mathavarajah S; Bera A; Salsman J; Habib E; Van Iderstine C; Bydoun M; Lewis SM; Dellaire G
FASEB J; 2021 Nov; 35(11):e22001. PubMed ID: 34674320
[TBL] [Abstract] [Full Text] [Related]
3. MicroRNA-3646 Contributes to Docetaxel Resistance in Human breast cancer Cells by GSK-3β/β-Catenin Signaling Pathway.
Zhang X; Zhong S; Xu Y; Yu D; Ma T; Chen L; Zhao Y; Chen X; Yang S; Wu Y; Tang J; Zhao J
PLoS One; 2016; 11(4):e0153194. PubMed ID: 27045586
[TBL] [Abstract] [Full Text] [Related]
4. Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women.
von Wolff M; Dittrich R; Liebenthron J; Nawroth F; Schüring AN; Bruckner T; Germeyer A
Reprod Biomed Online; 2015 Nov; 31(5):605-12. PubMed ID: 26380870
[TBL] [Abstract] [Full Text] [Related]
5. Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System.
Félix J; Andreozzi V; Soares M; Borrego P; Gervásio H; Moreira A; Costa L; Marcelo F; Peralta F; Furtado I; Pina F; Albuquerque C; Santos A; Passos-Coelho JL;
Value Health; 2011 Jun; 14(4):499-505. PubMed ID: 21669375
[TBL] [Abstract] [Full Text] [Related]
6. Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer.
Umar A; Kang H; Timmermans AM; Look MP; Meijer-van Gelder ME; den Bakker MA; Jaitly N; Martens JW; Luider TM; Foekens JA; Pasa-Tolić L
Mol Cell Proteomics; 2009 Jun; 8(6):1278-94. PubMed ID: 19329653
[TBL] [Abstract] [Full Text] [Related]
7. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
[TBL] [Abstract] [Full Text] [Related]
